drugset / Trial / NCT00003613
O6-benzylguanine and Carmustine in Treating Patients With Stage IA-IIA Cutaneous T-cell Lymphoma
NaSingle-groupOpen-labelTreatment
Summary
This phase I trial is studying the side effects and best dose of carmustine given together with O(6)-benzylguanine in treating patients with stage I or stage II cutaneous T-cell lymphoma that has not responded to previous treatment. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells
Timeline
- Start
- 1999-04
- Primary completion
- 2006-05
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | O6-benzylguanine | Small molecule | 120 mg/m2 | Intravenous |
| Subject | carmustine | Small molecule | 10 mg | Topical |
| Subject | carmustine | Small molecule | 20 mg | Topical |
| Subject | carmustine | Small molecule | 30 mg | Topical |
| Subject | carmustine | Small molecule | 40 mg | Topical |